Related Experiment Video

Updated: Jun 2, 2026

Transfer of Manipulated Tumor-associated Neutrophils into Tumor-Bearing Mice to Study their Angiogenic Potential In Vivo
08:19

Transfer of Manipulated Tumor-associated Neutrophils into Tumor-Bearing Mice to Study their Angiogenic Potential In Vivo

Published on: July 20, 2019

A novel antiangiogenic and vascular normalization therapy targeted against human CD160 receptor

Sophie Chabot1, Nabila Jabrane-Ferrat, Karine Bigot

  • 1Institut National de la Santé et de la Recherche Médicale U1043, F-31300 Toulouse, France.

The Journal of Experimental Medicine
|April 13, 2011
PubMed

Insights

A new monoclonal antibody, CL1-R2, targets CD160, effectively inhibiting pathological angiogenesis in eye diseases and tumors. This offers a promising new therapeutic avenue for resistant or unresponsive cases.

Area of Science:

  • Oncology
  • Ophthalmology
  • Immunology

Background:

  • Angiogenesis is crucial in ocular diseases and tumor growth.
  • Current antiangiogenic therapies have limitations in efficacy.
  • Pathological neovascularization requires novel therapeutic targets.

Purpose of the Study:

  • To investigate the antiangiogenic effects of monoclonal antibody CL1-R2.
  • To evaluate CL1-R2 as a potential therapeutic target for CD160.
  • To assess CL1-R2 efficacy in preclinical models of neovascularization.

Main Methods:

  • CL1-R2 was tested in rabbit cornea, mouse oxygen-induced retinopathy, and Matrigel plug assays.
  • CD160 expression was analyzed in tumor vasculature and healthy tissues.
  • CL1-R2 efficacy was assessed in combination with chemotherapy in melanoma models.

Main Results:

  • CL1-R2 targets CD160, expressed on neovascular endothelial cells but not in healthy tissues.
  • CL1-R2 demonstrated significant antiangiogenic effects in multiple preclinical models.
  • Combination therapy with CL1-R2 and chemotherapy regressed tumor vasculature and normalized remaining vessels.

Conclusions:

  • CD160 is a validated target for inhibiting pathological angiogenesis.
  • CL1-R2 shows potential as a novel therapeutic agent for resistant ocular and tumor neovascularization.
  • CL1-R2 offers a new strategy for treating angiogenesis-dependent diseases.

More Related Videos

Programming Stem Cells for Therapeutic Angiogenesis Using Biodegradable Polymeric Nanoparticles09:01

Programming Stem Cells for Therapeutic Angiogenesis Using Biodegradable Polymeric Nanoparticles

Published on: September 27, 2013

Preparation Of Neovascular Tissues from Human Glioma Tissues for Quantitative Proteomics Analysis of Tumor Angiogenesis09:33

Preparation Of Neovascular Tissues from Human Glioma Tissues for Quantitative Proteomics Analysis of Tumor Angiogenesis

Published on: March 20, 2026

Related Concept Videos

Regulation of Angiogenesis and Blood Supply01:24

Regulation of Angiogenesis and Blood Supply

Rapidly dividing tumors, embryos, and wounded tissues require more oxygen than usual, lowering the oxygen concentration in the blood. At low oxygen or hypoxic conditions, an oxygen-sensitive transcription factor called the hypoxia-inducible factor 1 or HIF1 is activated. HIF1 is a dimeric protein of alpha (ɑ) and beta (β) subunits.  Under optimal oxygen conditions, HIF1β is present in the nucleus while HIF1ɑ remains in the cytosol. HIF1ɑ is hydroxylated by prolyl hydroxylase and factor...
Mechanism of Angiogenesis01:10

Mechanism of Angiogenesis

Blood vessel formation starts early during embryonic development, around day 7. In the extraembryonic yolk sac, mesodermal precursor cells called hemangioblast proliferate and differentiate into angioblast. Angioblasts express vascular endothelial growth factor receptor 2 or VEGFR2, which binds VEGF-A, a proangiogenic factor, guiding blood vessel formation. VEGF signaling promotes angioblasts to form a blood island in the developing embryo. Angioblasts further differentiate, giving rise to...
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...
Treatment for Pulmonary Arterial Hypertension: Endothelin Receptor Antagonists01:18

Treatment for Pulmonary Arterial Hypertension: Endothelin Receptor Antagonists

Endothelins (ETs) are potent vasoactive peptides critical in the human body's various physiological and pathological processes. One of the most promising therapeutic strategies for treating pulmonary arterial hypertension (PAH) involves counteracting the effects of these endothelins using a class of drugs known as endothelin receptor antagonists.
ETs are synthesized through a complex sequence of enzymatic steps, primarily involving an enzyme referred to as endothelin-converting enzyme (ECE). Of...